ImmunoCellular Therapeutics, a clinical-stage biotechnology company, reported Monday updated immune monitoring data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma and updated long-term survival data from the phase 1 trial of ICT-107.
ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Glioblastoma is the most common and most aggressive cancer that begins within the brain.
The updated immune response data from the phase 2 trial showed that treatment with ICT-107 resulted in the development of a measurable anti-tumor T cell response in some patients, which was associated with survival. The data demonstrated that immuno-monitoring can provide an early indication of patients responding to immunotherapy. In the current ongoing phase 3 registration trial of ICT-107, ImmunoCellular plans to perform immuno-monitoring to support the trial.
Meanwhile, the updated survival data from the phase 1 trial of ICT-107 showed that 19% of patients had long-term remission of greater than 8 years, with the longest remission being 9.6 years. Also, 38% of patients demonstrated long-term survival of greater than 8 years, with the longest survivor greater than 10.2 years. Immune response data showed a correlation between survival and cancer-stem-associated expression, and a trend toward greater CD8 T cell cytokine responses in long-term survivors.